NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Provided By PR Newswire

Last update: Mar 28, 2024

Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity

Phase 1 Trial of DA-1726 Expected to Dose First Patient in Second Quarter of 2024